Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-17
2010-06-22
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07741278
ABSTRACT:
The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided.
REFERENCES:
patent: 4263279 (1981-04-01), Sela et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4666845 (1987-05-01), Mattes et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4771128 (1988-09-01), Ferris et al.
patent: 4801578 (1989-01-01), Monsigny et al.
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4870163 (1989-09-01), Rubin et al.
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4894225 (1990-01-01), Zimmerman
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4894443 (1990-01-01), Greenfield et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4962188 (1990-10-01), Frankel
patent: 4963354 (1990-10-01), Shepard et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 4980457 (1990-12-01), Jansen et al.
patent: 5017371 (1991-05-01), Cummins
patent: 5019368 (1991-05-01), Epstein et al.
patent: 5032521 (1991-07-01), White et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5621083 (1997-04-01), Better et al.
patent: 5624827 (1997-04-01), Rosenblum et al.
patent: 5631348 (1997-05-01), Rosenblum et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5744580 (1998-04-01), Better et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5830880 (1998-11-01), Sedlacek et al.
patent: 5837491 (1998-11-01), Better et al.
patent: 5851815 (1998-12-01), Alnemri et al.
patent: 5851829 (1998-12-01), Marasco et al.
patent: 6084073 (2000-07-01), Piatak, Jr.
patent: 6099842 (2000-08-01), Pastan et al.
patent: 6140066 (2000-10-01), Lorberboum-Galski et al.
patent: 6197528 (2001-03-01), Wu et al.
patent: 6214974 (2001-04-01), Rosenblum et al.
patent: 6218165 (2001-04-01), Estell et al.
patent: 6306626 (2001-10-01), Rosenblum et al.
patent: 6309873 (2001-10-01), Torrens Madrazo et al.
patent: RE37462 (2001-12-01), Rosenblum et al.
patent: 6531133 (2003-03-01), Lorberboum-Galski et al.
patent: 6599505 (2003-07-01), Rosenblum
patent: 6639054 (2003-10-01), Alibhai et al.
patent: 6645490 (2003-11-01), Yarkoni et al.
patent: 6669938 (2003-12-01), Rosenblum et al.
patent: 6703020 (2004-03-01), Thorpe et al.
patent: 6750329 (2004-06-01), Rosenblum et al.
patent: 7083957 (2006-08-01), Rosenblum et al.
patent: 2002/0090374 (2002-07-01), Yarkoni et al.
patent: 2003/0073163 (2003-04-01), Fernandez et al.
patent: 2003/0086919 (2003-05-01), Rosenblum et al.
patent: 2003/0134302 (2003-07-01), Fernandez et al.
patent: 2003/0176331 (2003-09-01), Rosenblum et al.
patent: 2003/0186384 (2003-10-01), Barth et al.
patent: 2004/0009477 (2004-01-01), Fernandez et al.
patent: 2004/0013691 (2004-01-01), Rosenblum
patent: 2005/0100528 (2005-05-01), Rosenblum
patent: 2005/0214307 (2005-09-01), Rosenblum
patent: B79527/87 (1988-04-01), None
patent: B82047/87 (1988-06-01), None
patent: A13017/88 (1988-09-01), None
patent: A21725/88 (1989-03-01), None
patent: A30753/89 (1989-08-01), None
patent: 1339798 (1998-04-01), None
patent: 0118365 (1984-03-01), None
patent: 0160446 (1985-04-01), None
patent: 0150126 (1985-07-01), None
patent: 0184369 (1985-11-01), None
patent: 0226418 (1986-12-01), None
patent: 0222360 (1987-05-01), None
patent: 0256714 (1988-02-01), None
patent: 0281070 (1988-09-01), None
patent: 0305967 (1989-03-01), None
patent: 0336631 (1989-10-01), None
patent: 0350230 (1990-01-01), None
patent: 0396387 (1990-11-01), None
patent: 0893493 (1999-01-01), None
patent: 1564666 (1978-01-01), None
patent: 2148299 (1985-05-01), None
patent: 86121 (1981-07-01), None
patent: 62209098 (1986-12-01), None
patent: 190200 (1987-08-01), None
patent: 8-510642 (1996-11-01), None
patent: WO 85/00974 (1985-03-01), None
patent: WO 86/02945 (1986-05-01), None
patent: WO 86/05098 (1986-09-01), None
patent: WO 87/00056 (1987-01-01), None
patent: WO 88/09343 (1988-12-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/00999 (1989-02-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 90/00405 (1990-01-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 91/16071 (1991-10-01), None
patent: WO 94/26910 (1994-11-01), None
patent: WO 97/22364 (1997-06-01), None
patent: WO 97/46259 (1997-12-01), None
patent: WO 98/37901 (1998-09-01), None
patent: WO 99/09206 (1999-02-01), None
patent: WO 99/29721 (1999-06-01), None
patent: WO 99/40198 (1999-08-01), None
patent: WO 99/43840 (1999-09-01), None
patent: WO 99/45128 (1999-09-01), None
patent: WO 99/49059 (1999-09-01), None
patent: WO 99/51620 (1999-10-01), None
patent: WO 99/51766 (1999-10-01), None
patent: WO 00/26406 (2000-05-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 00/42179 (2000-07-01), None
patent: WO 02/42420 (2002-05-01), None
patent: WO 02/074979 (2002-09-01), None
patent: WO 03/002598 (2003-01-01), None
Aboud-Pirak et al., “Cytotoxic activity of daunorubicin or vindesine conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells,”Biochem. Pharmacol., 38:641-648, 1989.
Adams et al., “The Bcl-2 Protein Family: Arbiters of Cell Survival,”Science, 281:1322-1326, 1998.
Aggarwal and Kohr, “Human tumor necrosis factor,”Methods in Enzymology, 116:448-456, 1986.
Alfthan et al., “Properties of single-chain antibody containing different linker peptides,”Protein Engineering; 8:725-731, 1995.
Alkan et al., “Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies,”J. Interferon Res., 4(3):355-363, 1984.
Alley et al., “Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay,”Cancer Res., 48:589-601, 1988.
Aqeilan et al., “Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy,”FEBS Letters, 457:271-276, 1999.
Ardekani et al., “Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies,”Current Therapeutic Res., 62:803-819, 2001.
Arnon et al., “Monoclonal antibodies for immunotargeting of drugs in cancer therapy,” Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. pp. 243-256, 1985.
Arora, “Vascular endothelial growth facto chimeric toxin is highly active against endothelial cells,”Cancer Research, 59:183-188, 1999.
Atkinson et al., “Conjugation of folate via gelonin carbohydrate residues retains ribosomal-activating properties of the toxin and permits targeting to folate receptor positive cells,”Biochem Molec. Biol., 276(30):27930-27935, 2001.
Barbieri and Stirpe, “Ribosome-inactivating proteins from plants: Properties and possible uses,”Cancer Surveys, 1(3):489-520.
Batra et al., “Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin,”Proc. Natl. Acad. Sci., 86:8545-8549, 1989.
Batra at al., “Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv),”Mol. Cell. Biol.11:2200-2205, 1991.
Bendig, “Humanization of rodent monoclonal antibodies by C
Cheung Lawrence
Rosenblum Michael G.
Carlson Karen Cochrane
Fulbright & Jaworski
Research Development Foundation
LandOfFree
Modified proteins, designer toxins, and methods of making... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified proteins, designer toxins, and methods of making..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified proteins, designer toxins, and methods of making... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248269